fingolimod (Gilenya) vs Siponimod (Mayzent)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: S1P receptor · full Multiple Sclerosis pipeline
fingolimod (Gilenya)
Marketed by Novartis and partners
NCT00289978 · Phase 3 · completed
This was a large randomized, triple-blind, placebo-controlled Phase 3 trial in 1,272 people with multiple sclerosis, using the annualized relapse rate as its primary measure. Both fingolimod doses roughly halved that rate against placebo: 0.16 relapses per year (95% CI 0.13 to 0.19) on 1.25 mg and 0.18 (95% CI 0.15 to 0.22) on 0.5 mg, against 0.40 (95% CI 0.34 to 0.47) on placebo. The registry posts these rates without a statistical test, but the intervals do not overlap, so the direction of the effect is not in doubt.
Next expected readout: January 2030 · NCT07220252 (registry estimate)
Reported efficacy
Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Estimated Annualized Aggregate Relapse Rate (ARR) (Baseline to end of study (Month 24)): Fingolimod 1.25 mg 0.16 Relapses per year (95% CI 0.13 to 0.19) | Fingolimod 0.5 mg 0.18 Relapses per year (95% CI 0.15 to 0.22) vs Placebo 0.4 Relapses per year (95% CI 0.34 to 0.47) (met)
Result source: NCT00289978
Siponimod (Mayzent)
Marketed by Novartis
NCT03623243 · Phase 3 · completed
The study was an open-label, single-arm trial with 185 participants and no placebo or active comparator, so its findings are descriptive rather than a controlled comparison. Its primary clinical endpoint was the number of participants with treatment-emergent adverse events related to siponimod; 59 participants were reported with such an event, but no comparative significance test was applicable.
Reported efficacy
Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS) (Baseline, every 3 month up to the maximum of approximately 3 years): EXPAND (n=1,651), primary endpoint 3-month confirmed disability progression on EDSS: 26.3% with siponimod vs 31.7% with placebo; HR 0.79 (95% CI 0.65 to 0.95), Cox model p=0.0134 (CT.gov posted results). (met)
Result source: NCT01665144
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fingolimod (Gilenya) | Siponimod (Mayzent) |
|---|---|---|
| Annualised relapse rate | 0.2 vs 0.4−0.2 vs placeboNCT002899785 other results
| —Trial running · NCT04926818 |
| Free of 3-month confirmed disability progression (%) | 82.3% vs 75.9%+6.4 vs placeboNCT002899783 other results
| —Trial running · NCT04926818 |
| New or enlarging T2 lesions | 2.5 vs 9.8−7.3 vs placeboNCT002899781 other result
| —Trial running · NCT04926818 |
Annualised relapse rate
- fingolimod (Gilenya)
- 0.2 vs 0.4−0.2 vs placeboNCT00289978
5 other results
- 0.2 vs 0.4 NCT00355134
- 0.2 vs 0.4 NCT00289978
- 0.2 vs 0.4 NCT00355134
- 0.2 vs 0.4 NCT00355134
- 0.2 vs 0.4 NCT00355134
- Siponimod (Mayzent)
- —Trial running · NCT04926818
Free of 3-month confirmed disability progression (%)
- fingolimod (Gilenya)
- 82.3% vs 75.9%+6.4 vs placeboNCT00289978
3 other results
- 74.7% vs 71% NCT00355134
- 83.4% vs 75.9% NCT00289978
- 78.3% vs 71% NCT00355134
- Siponimod (Mayzent)
- —Trial running · NCT04926818
New or enlarging T2 lesions
- fingolimod (Gilenya)
- 2.5 vs 9.8−7.3 vs placeboNCT00289978
1 other result
- 2.5 vs 9.8 NCT00289978
- Siponimod (Mayzent)
- —Trial running · NCT04926818
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. fingolimod (Gilenya): 4 of 4 rows · Siponimod (Mayzent): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fingolimod (Gilenya) | Siponimod (Mayzent) |
|---|---|---|
| Dropout rate | 13.2%0.5 mga NCT00289978 · Phase 3 · monotherapy show 44 more results22.6%1.25 mg NCT00289978 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy 7.7%0.5 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy 13.4%1.25 mg NCT00340834 · Phase 3 · monotherapy 13.2%0.5 mg NCT00662649 · Phase 3 · monotherapy —0.5 mg NCT00662649 · Phase 3 —0.5 mg NCT00662649 · Phase 3 22.6%1.25 mg NCT00662649 · Phase 3 · monotherapy —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy 9.1%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 13.8%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 33.3% NCT02232061 · Phase 4 · registry result, not featured evidence 43%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 15.7%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 31% NCT01705236 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02373098 · Phase 4 · registry result, not featured evidence 18.2%FTY720 NCT02373098 · Phase 4 · registry result, not featured evidence 0.5% NCT01585298 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02720107 · Phase 4 · registry result, not featured evidence 8%Naive or de Novo Participants NCT01498887 · Phase 4 · registry result, not featured evidence 7.5%Previously Treated With First-line NCT01498887 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01333501 · Phase 4 · registry result, not featured evidence 14.2% NCT01623596 · Phase 4 · registry result, not featured evidence 12.1% NCT02048072 · Phase 4 · registry result, not featured evidence 16.7% NCT01578330 · Phase 4 · registry result, not featured evidence 5.2%0.5 mg NCT01534182 · Phase 4 · registry result, not featured evidence 9.6%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence —0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 15.6%0.5 mg/Day NCT01201356 · Phase 3 · registry result, not featured evidence 6.8%0.5 mg NCT01497262 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 24%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 32.2%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 2.1% NCT01199861 · Phase 3 · registry result, not featured evidence 19.1%0.5 mg NCT00670449 · Phase 2 · registry result, not featured evidence 21.7%1.25 mg NCT00670449 · Phase 2 · registry result, not featured evidence | 21.1%a NCT03623243 · Phase 3 |
| Discontinued due to AEs | 3.1%0.5 mga NCT00289978 · Phase 3 · monotherapy show 44 more results5.1%1.25 mg NCT00289978 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy 2.1%0.5 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy 6.1%1.25 mg NCT00340834 · Phase 3 · monotherapy 3.1%0.5 mg NCT00662649 · Phase 3 · monotherapy —0.5 mg NCT00662649 · Phase 3 —0.5 mg NCT00662649 · Phase 3 5.1%1.25 mg NCT00662649 · Phase 3 · monotherapy —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy 0%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 2.3%0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence — NCT02232061 · Phase 4 · registry result, not featured evidence 15.2%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 5.5%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 5.7% NCT01705236 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02373098 · Phase 4 · registry result, not featured evidence 4.5%FTY720 NCT02373098 · Phase 4 · registry result, not featured evidence 0.3% NCT01585298 · Phase 4 · registry result, not featured evidence —0.5 mg NCT02720107 · Phase 4 · registry result, not featured evidence 2%Naive or de Novo Participants NCT01498887 · Phase 4 · registry result, not featured evidence 0.7%Previously Treated With First-line NCT01498887 · Phase 4 · registry result, not featured evidence —0.5 mg NCT01333501 · Phase 4 · registry result, not featured evidence 4.6% NCT01623596 · Phase 4 · registry result, not featured evidence 9.1% NCT02048072 · Phase 4 · registry result, not featured evidence 4.8% NCT01578330 · Phase 4 · registry result, not featured evidence 3%0.5 mg NCT01534182 · Phase 4 · registry result, not featured evidence 5.1%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence —0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 4.1%0.5 mg/Day NCT01201356 · Phase 3 · registry result, not featured evidence 1.2%0.5 mg NCT01497262 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 6.1%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 7.6%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 1.1% NCT01199861 · Phase 3 · registry result, not featured evidence 12.8%0.5 mg NCT00670449 · Phase 2 · registry result, not featured evidence 4.3%1.25 mg NCT00670449 · Phase 2 · registry result, not featured evidence | 8.1%a NCT03623243 · Phase 3 |
| Serious AEs | 10.1%0.5 mga NCT00289978 · Phase 3 · monotherapy show 44 more results11.9%1.25 mg NCT00289978 · Phase 3 · monotherapy 7%0.5 mg NCT00340834 · Phase 3 · monotherapy 14.5%0.5 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00340834 · Phase 3 · monotherapy 10.7%1.25 mg NCT00340834 · Phase 3 · monotherapy 15.3%1.25 mg NCT00340834 · Phase 3 · monotherapy —1.25 mg NCT00340834 · Phase 3 · monotherapy —0.5 mg NCT00662649 · Phase 3 · monotherapy 9.4%0.5 mg NCT00662649 · Phase 3 7.1%0.5 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy 10.7%1.25 mg NCT00662649 · Phase 3 11.7%1.25 mg NCT00662649 · Phase 3 —1.25 mg NCT00662649 · Phase 3 · monotherapy —0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence —0.5 mg NCT04667949 · Phase 4 · registry result, not featured evidence 33.3% NCT02232061 · Phase 4 · registry result, not featured evidence 5.5%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 5.5%0.5 mg NCT03257358 · Phase 4 · registry result, not featured evidence 12.6% NCT01705236 · Phase 4 · registry result, not featured evidence 4.5%0.5 mg NCT02373098 · Phase 4 · registry result, not featured evidence —FTY720 NCT02373098 · Phase 4 · registry result, not featured evidence 2.3% NCT01585298 · Phase 4 · registry result, not featured evidence 0%0.5 mg NCT02720107 · Phase 4 · registry result, not featured evidence 5.5%Naive or de Novo Participants NCT01498887 · Phase 4 · registry result, not featured evidence 2.7%Previously Treated With First-line NCT01498887 · Phase 4 · registry result, not featured evidence 8.7%0.5 mg NCT01333501 · Phase 4 · registry result, not featured evidence 6.7% NCT01623596 · Phase 4 · registry result, not featured evidence 6.1% NCT02048072 · Phase 4 · registry result, not featured evidence 9.5% NCT01578330 · Phase 4 · registry result, not featured evidence 0.9%0.5 mg NCT01534182 · Phase 4 · registry result, not featured evidence 4%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 3.6%0.5 mg/day NCT01216072 · Phase 4 · registry result, not featured evidence 12.6%0.5 mg/Day NCT01201356 · Phase 3 · registry result, not featured evidence 7.4%0.5 mg NCT01497262 · Phase 3 · registry result, not featured evidence 14.8%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 6.5%0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence —0.5 mg NCT00355134 · Phase 3 · registry result, not featured evidence 14.3%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 8.8%1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence —1.25 mg NCT00355134 · Phase 3 · registry result, not featured evidence 1.1% NCT01199861 · Phase 3 · registry result, not featured evidence 17%0.5 mg NCT00670449 · Phase 2 · registry result, not featured evidence 10.9%1.25 mg NCT00670449 · Phase 2 · registry result, not featured evidence | 4.9%a NCT03623243 · Phase 3 |
| Most frequent reported AEs | 0.5 mga nasopharyngitis 27.1% (placebo 27.5%) headache 25.2% (placebo 23%) upper respiratory tract infection 17.2% (placebo 17.2%) NCT00289978 · Phase 3 · monotherapy show 34 more results1.25 mg headache 26.3% (placebo 23%) nasopharyngitis 26.1% (placebo 27.5%) upper respiratory tract infection 14.5% (placebo 17.2%) NCT00289978 · Phase 3 · monotherapy 0.5 mg nasopharyngitis 25.4% upper respiratory tract infection 17.5% lymphopenia 15.7% NCT00662649 · Phase 3 0.5 mg nasopharyngitis 28.4% headache 16.8% upper respiratory tract infection 15.5% NCT00662649 · Phase 3 1.25 mg nasopharyngitis 28.4% lymphopenia 18% upper respiratory tract infection 13.5% NCT00662649 · Phase 3 1.25 mg nasopharyngitis 26.9% upper respiratory tract infection 15.9% headache 12.4% NCT00662649 · Phase 3 anxiety 16.7% bursitis 16.7% facet joint syndrome 16.7% NCT02232061 · Phase 4 · registry result, not featured evidence 0.5 mg headache 8% lymphopenia 5.5% pain in extremity 5.5% NCT03257358 · Phase 4 · registry result, not featured evidence 0.5 mg fall 5.5% urinary tract infection 3.2% arthralgia 2.8% NCT03257358 · Phase 4 · registry result, not featured evidence nasopharyngitis 47.1% multiple sclerosis relapse 24.1% hypertension 13.8% NCT01705236 · Phase 4 · registry result, not featured evidence 0.5 mg influenza 3% gamma-glutamyltransferase increased 1.5% headache 1.5% NCT02373098 · Phase 4 · registry result, not featured evidence headache 4.5% fatigue 3.2% nasopharyngitis 2% NCT01585298 · Phase 4 · registry result, not featured evidence 0.5 mg blood immunoglobulin m decreased 0.8% NCT02720107 · Phase 4 · registry result, not featured evidence headache 8.5% nasopharyngitis 8% upper respiratory tract infection 7.5% NCT01498887 · Phase 4 · registry result, not featured evidence headache 11.6% urinary tract infection 10.2% upper respiratory tract infection 8.2% NCT01498887 · Phase 4 · registry result, not featured evidence 0.5 mg headache 10.6% alanine aminotransferase increased 8.7% depression 6.7% NCT01333501 · Phase 4 · registry result, not featured evidence fatigue 11.3% nasopharyngitis 9.5% headache 9.2% NCT01623596 · Phase 4 · registry result, not featured evidence exacerbation of migraines 3% NCT02048072 · Phase 4 · registry result, not featured evidence urinary infection 21.4% upper respiratory infection 19% lymphopenia 16.7% NCT01578330 · Phase 4 · registry result, not featured evidence 0.5 mg lymphopenia 11.7% gamma-glutamyltransferase increased 5.7% alanine aminotransferase increased 4.8% NCT01534182 · Phase 4 · registry result, not featured evidence 0.5 mg/day headache 12.4% fatigue 11.5% upper respiratory tract infection 6.5% NCT01216072 · Phase 4 · registry result, not featured evidence 0.5 mg/day headache 9.8% nausea 5.7% fatigue 5.2% NCT01216072 · Phase 4 · registry result, not featured evidence 0.5 mg/Day nasopharyngitis 17.3% headache 8.5% upper respiratory tract infection 8.5% NCT01201356 · Phase 3 · registry result, not featured evidence 0.5 mg headache 13.6% lymphopenia 10.5% fatigue 6.2% NCT01497262 · Phase 3 · registry result, not featured evidence 0.5 mg upper respiratory tract infection 24.3% (placebo 24.2%) nasopharyngitis 23.5% (placebo 23.9%) headache 23.2% (placebo 21.4%) NCT00355134 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 16% (placebo 23.9%) upper respiratory tract infection 12.3% (placebo 24.2%) headache 9% (placebo 21.4%) NCT00355134 · Phase 3 · registry result, not featured evidence 1.25 mg upper respiratory tract infection 24.9% (placebo 24.2%) nasopharyngitis 23.8% (placebo 23.9%) headache 21.9% (placebo 21.4%) NCT00355134 · Phase 3 · registry result, not featured evidence 1.25 mg nasopharyngitis 16.2% (placebo 23.9%) upper respiratory tract infection 15.9% (placebo 24.2%) sinusitis 10.1% (placebo 12.7%) NCT00355134 · Phase 3 · registry result, not featured evidence headache 18.9% (placebo 9.3%) nasopharyngitis 15.8% (placebo 18.6%) upper respiratory tract infection 11.6% (placebo 14%) NCT01199861 · Phase 3 · registry result, not featured evidence 0.5 mg nasopharyngitis 61.7% headache 17% liver function test abnormal 12.8% NCT00670449 · Phase 2 · registry result, not featured evidence 1.25 mg nasopharyngitis 60.9% liver function test abnormal 17.4% lymphopenia 17.4% NCT00670449 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fingolimod (Gilenya)
show 5 more results
show 3 more results
show 1 more result
show 17 more results
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 9 more results
show 1 more result
show 23 more results
+ 144 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fingolimod (Gilenya)'s landscape · Siponimod (Mayzent)'s landscape